| Trial ID: | L7097 |
| Source ID: | NCT00497198
|
| Associated Drug: |
Mci-196
|
| Title: |
Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00497198/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: MCI-196|DRUG: Placebo of MCI-196 Tablet
|
| Outcome Measures: |
Primary: Fasting Plasma Glucose at Baseline, 0 weeks|Change From Baseline in Blood Glucose at Week 12, 12 weeks (baseline to week 12)|Hemoglobin A1c (HbA1c) at Baseline, 0 weeks|Change From Baseline in Hemoglobin A1c(HbA1c) at Week 12, 12 weeks (baseline to week 12) | Secondary: Change From Baseline in Low Density Lipoprotein Cholesterol(LDL-c) at Week 12, 12 weeks (baseline to week 12)
|
| Sponsor/Collaborators: |
Sponsor: Mitsubishi Tanabe Pharma Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
183
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-10
|
| Completion Date: |
2007-09
|
| Results First Posted: |
2011-08-11
|
| Last Update Posted: |
2012-06-08
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00497198
|
